Longboard (LBPH): Growth-Adjusted P/E Ratio
Longboard Pharmaceuticals (LBPH), which has earned the trust of physicians through the safety of its pediatric epilepsy treatments, is now fully integrated into a European behemoth following an acquisition deal. The peg_co multiplier confirms this status, with the 0.00 mark reflecting the asset's current valuation. Specialization in the targeted action of brain GPCR receptors for rare pathologies paves the way for leadership in a multi-billion dollar market.
Analytical breakdowns for Longboard Pharmaceuticals (LBPH)
- current quotes and average value forecast:
- stock exchange capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Capital Longboard Pharmaceuticals|LBPH - Long-Term Debt to Capital|Short-Term Debt to Capital longboardpharma.com|LBPH - Company Debts|Debt to Net Assets Ratio Longboard Pharma|LBPH - Company Long-Term Debts|Company Short-Term Indebtedness Longboard Pharmaceuticals|Intermediate Coverage Ratio longboardpharma.com
- earnings and market multiples details:
LBPH - Company Net Income|Forward Earnings Longboard Pharmaceuticals|LBPH - P/E Multiple|Future Price to Earnings Multiple Longboard|LBPH - PEG Multiple|EV/EBITDA Multiple Longboard Pharma|LBPH - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Longboard Pharmaceuticals|LBPH - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months longboardpharma.com|LBPH - Earnings growth in current year|Earnings growth forecast for next year Longboard Pharmaceuticals
Fundamental company analysis:Longboard Pharmaceuticals Inc, LBPH
The PEG ratio compares the P/E ratio with earnings growth rates, identifying assets whose market value lags behind operational development. By analyzing the peg_co multiplier, an investor can see how Longboard Pharmaceuticals (LBPH) long-term component supply contracts for neurological drugs minimize research disruption risks, creating a foundation for sustainable growth that the market may be underpricing.
Competing companies
BIIB - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Neurocrine Biosciences Inc NBIX|RGC: Growth-Adjusted P/E Ratio|Axsome Therapeutics - PEG Multiple|Price to Net Income Growth Ratio acadia-pharm.com (ACAD)|XENE: PEG Multiple|VKTX (Viking Therapeutics Inc) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Ratio Supernus Pharma|Price to Earnings Adjusted for Growth Rate Catalyst Corp CPRX|PEG Multiple DNLI|PEG Multiple harmonybiosciences.com (HRMY)|Price/Earnings to Growth Ratio Biohaven BHVN|Growth-Adjusted Payback Ratio AMLX|Trevi Pharma - PEG Multiple|PRAX (Praxis Corp) - Growth-Adjusted P/E Ratio|AVXL (Anavex Life Sciences) - Price/Earnings to Growth Multiple|ceribell.com - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Prothena Corporation plc|Alector Therapeutics - Market Cap to Earnings and Growth Ratio|PEG Multiple ANNX|OMER (omeros.com) - Growth-Adjusted Payback Ratio|PEG Multiple NGNE (Neurogene Inc.)|PEG Multiple acimmune.com ACIU|VYGR - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio NMRA (Neumora)|Scilex Holding Co. (SCLX) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Tevogen Bio Inc.|ACOG (Alpha Cognition Inc) - PEG Multiple|PEG Multiple cogrx.com|PEG Multiple IKT|Price/Earnings to Growth Multiple Cassava Sciences Inc SAVA|PEG Multiple ASRT (Assertio)|Coya Therapeutics Inc (COYA) - Price to Earnings Adjusted for Growth Rate|VTGN: Price/Earnings to Growth Multiple|OVID - PEG Multiple|ABOS (Acumen Pharmaceuticals, Inc.) - Price/Earnings to Growth Multiple|CRVO: Company Value to Earnings Growth Ratio|ATHE (Alterity Therapeutics Ltd.) - PEG Multiple|Clene Nanomedicine (CLNN) - Growth-Adjusted Market Cap to Net Income|PEG Multiple PEPG|Price/Earnings to Growth Multiple jupiterneurosciences.com JUNS|PEG Multiple RLMD (Relmada Therapeutics, Inc.)|PEG Multiple Annovis Bio Inc ANVS|GRCE - Price/Earnings to Growth Ratio|AIFF: Price/Earnings to Growth Ratio|anewmeds.com (KLTO) - Price/Earnings to Growth Ratio|NRSN - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Reviva Pharmaceuticals Holdings, Inc.|Price/Earnings to Growth Ratio MTVA|PEG Multiple NRXS|Price/Earnings to Growth Ratio HSDT (heliusmedical.com)|Price/Earnings to Growth Ratio Passage Bio PASG|NEUP (Neuphoria Therapeutics, Inc.) - Market Cap to Earnings and Growth Ratio|Minerva Neurosciences, Inc. - PEG Multiple|Growth-Adjusted Payback Ratio ATHA (Athira Pharma Inc)|Addex Therapeutics, Ltd. (ADXN) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio ALZN|CYCN (Cyclerion Therapeutics Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Protagenic PTIX|Price/Earnings to Growth Multiple KTTA (Pasithea Therapeutics)|PEG Multiple cortigent.com (CRGT)|Price/Earnings to Growth Ratio Avenue Therapeutics, Inc ATXI|Growth-Adjusted Payback Ratio BCLI|CARA - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate chromocell.com|eliemtx.com (ELYM) - Price/Earnings to Growth Ratio|ITCI (Intra-Cellular Therapies, Inc.) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Ratio Marinus|Price to Earnings Adjusted for Growth Rate NKGen Biotech Corp NKGN|Price/Earnings to Growth Ratio NeuroBo Pharmaceuticals (NRBO)|sagerx.com - Growth-Adjusted P/E Ratio|PEG Multiple SNPX (Synaptogenix)|Price to Net Income Growth Ratio Trevena Inc.|Vigil Neuro - PEG Multiple|WENA: Price/Earnings to Growth Ratio|Cerevel Therapeutics (CERE) - Price/Earnings to Growth Ratio
